Plain-English translation of NCT06998862 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether colchicine, a medication that reduces inflammation in the body, can help prevent serious heart and stroke events and slow down kidney damage in people with moderate chronic kidney disease who have already experienced heart or blood vessel problems. About 744 patients will participate, with half receiving the medication and half receiving a placebo (a dummy pill). The study will last three years.
People with chronic kidney disease are at high risk for heart attacks and strokes, and their kidneys often continue to decline over time. Researchers want to see whether reducing inflammation with this medication might help prevent these serious complications and protect kidney function.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either one daily colchicine tablet or a placebo pill for three years. You will visit the clinic regularly for blood and urine tests to monitor your kidney function, heart health, and inflammation markers. The study team will track whether you experience any heart problems, strokes, or changes in your kidney function over this time period.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Spain